LISATA THERAPEUTICS, INC. — Director's Dealing 2015

Jan 22, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NeoStem, Inc. (NBS)
CIK: 0000320017
Period of Report: 2015-01-22

Reporting Person: TRABER PETER G (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-01-22	Stock Option (right to purchase)	$3.56	A	26500	Acquired	2025-01-21	Common Stock, par value $0.001 per share (26500)	Direct

Footnotes

F1: Effective January 22, 2015 (the "Grant Date"), NeoStem, Inc. (the "Company") appointed Peter G. Traber, MD (the "Reporting Person") as a director of the Company and the Chair of its Science and Technology Committee. In connection with the appointment, the Reporting Person was granted an option to purchase 26,500 shares of the Company's common stock (the "Option"), subject to all of the terms and conditions of the Company's 2009 Amended & Restated Equity Compensation Plan and pursuant to the Company's Director Compensation Plan. The Option was fully vested on the Grant Date.